Severe Chronic Hand Eczema: Monthly Costs and Productivity in 104 Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of fictional people and work settings, not a patient, diagnosis, before-and-after image or Dr. Arsy #003 result.
The practical question
Productivity was the largest single cost component in this selected severe cohort.
The study is most useful when its population, design, denominator and timepoint stay attached. A percentage from a clinic, registry, survey or prevention program is not an individual prediction and cannot diagnose the cause of a rash.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 104 adults with severe chronic hand eczema considered refractory to topical corticosteroids |
| Design | Cross-sectional resource-use, productivity and health-utility study |
| Timepoint | Monthly cost estimate at study assessment |
| Key result | Mean societal cost was €418.30 per patient-month; productivity accounted for 43.7%, hospitalization 16.1% and travel 10.3%; mean EQ-5D utility was 0.50 and DLQI 11.3 |
Reading the result carefully
Mean societal cost was €418.30 per patient-month; productivity accounted for 43.7%, hospitalization 16.1% and travel 10.3%; mean EQ-5D utility was 0.50 and DLQI 11.3.
The sample was small and highly selected, resource prices were country- and time-specific, and a mean monthly estimate can conceal major variation.
That distinction matters. A correlation can identify a pattern without proving cause. A before-and-after program can show change without showing which component produced it. A mean can also conceal a smaller group with persistent severe disease, very high cost or prolonged absence.
What this can mean at work
Measure the worker’s time cost—absence, slowed tasks, travel and treatment time—alongside clinical outcomes.
A useful occupational history identifies the exact task, material, frequency, wet-work time, glove type, cleaning method, symptom timing and functional effect. Prevention follows a hierarchy: eliminate or substitute hazards where feasible, control the process, train the worker, and then use correctly selected protective equipment. Moisturizer can support dry-skin comfort; it cannot neutralize a hazardous exposure.
Questions to bring to care
- Which diagnosis and exposure hypothesis best fit the timing and distribution?
- Is clinician-directed patch testing or occupational review appropriate?
- What concrete outcome will be tracked: severity, sleep, function, absence, productivity or job retention?
- What would trigger urgent evaluation, such as rapidly spreading redness, drainage, fever, severe pain or major functional loss?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 24102212
- NIAMS: atopic dermatitis overview
- American Academy of Dermatology: skin-care guidance
- NIOSH: occupational skin-exposure recommendations
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and external results do not become product results. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is the narrow one: preserve the denominator, comparator, timepoint and limitations, then use the study to ask better clinical and workplace questions rather than to promise a universal result.
Educational content only. Researchers and cited organizations do not endorse Dr. Arsy.